Hydralazine

Generic Name
Hydralazine
Brand Names
Apresoline, Bidil
Drug Type
Small Molecule
Chemical Formula
C8H8N4
CAS Number
86-54-4
Unique Ingredient Identifier
26NAK24LS8
Background

Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure. Hydralazine is no longer a first line therapy for thes...

Indication

Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension. A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.

Associated Conditions
Heart Failure, Hypertension, Essential Hypertension, Hypertensive crisis, Severe Hypertension
Associated Therapies
-

Black Education and Treatment of Hypertension (BEAT HTN)

First Posted Date
2008-04-21
Last Posted Date
2012-12-04
Lead Sponsor
Creighton University
Target Recruit Count
99
Registration Number
NCT00661895
Locations
🇺🇸

Creighton Community Health Center, Omaha, Nebraska, United States

Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2008-02-05
Last Posted Date
2014-06-10
Lead Sponsor
University of Chicago
Target Recruit Count
2
Registration Number
NCT00607477
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Sildenafil and Exercise Capacity in Hypertension

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-01-23
Last Posted Date
2010-04-08
Lead Sponsor
University of Edinburgh
Target Recruit Count
30
Registration Number
NCT00599235
Locations
🇬🇧

University of Edinburgh - Western General Hospital, Edinburgh, United Kingdom

Hydralazine as a Demethylating Agent in Rectal Cancer

Phase 1
Withdrawn
Conditions
Interventions
First Posted Date
2007-12-18
Last Posted Date
2015-03-04
Lead Sponsor
University of Arkansas
Registration Number
NCT00575640

Hydralazine as Demethylating Agent in Breast Cancer

Phase 1
Withdrawn
Conditions
Interventions
First Posted Date
2007-12-18
Last Posted Date
2015-03-04
Lead Sponsor
University of Arkansas
Registration Number
NCT00575978

African-American Heart Failure Trial

Phase 4
Completed
Conditions
First Posted Date
2002-10-21
Last Posted Date
2005-06-24
Lead Sponsor
Nitromed
Target Recruit Count
1100
Registration Number
NCT00047775
Locations
🇺🇸

Minneapolis VA Medical Center, Minneapolis, Minnesota, United States

🇺🇸

Saint Vincents Hospital and Medical Center, New York, New York, United States

🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

and more 4 locations

Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)

First Posted Date
1999-10-28
Last Posted Date
2013-11-26
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000499
© Copyright 2024. All Rights Reserved by MedPath